歡迎光臨源葉生物,登錄 | 注冊 |
當(dāng)前位置: 首頁 > 小分子抑制劑 > Chromatin/Epigenetic > RVX 208

瀏覽歷史

S80050

RVX 208

源葉(MedMol) 99%
  • 英文名:
  • Apabetalone
  • 別名:
  • 2-[3,5-二甲基-4-(2-羥基乙氧基)苯基]-5,7-二甲氧基喹唑啉-4(3H)-酮
  • CAS號:
  • 1044870-39-4
  • 分子式:
  • C20H22N2O5
  • 分子量:
  • 370.4
  • 核磁/質(zhì)譜:
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計量單位 加入購物車...
源葉(MedMol) S80050-2mg 99% ¥100.00元 4 - - - EA 加入購物車
源葉(MedMol) S80050-5mg 99% ¥144.00元 8 - - - EA 加入購物車
源葉(MedMol) S80050-10mg 99% ¥204.00元 7 - - - EA 加入購物車
源葉(MedMol) S80050-25mg 99% ¥370.00元 8 - - - EA 加入購物車
源葉(MedMol) S80050-50mg 99% ¥510.00元 預(yù)計交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S80050-100mg 99% ¥760.00元 4 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權(quán)與保護申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻

質(zhì)檢證書(COA)

摩爾濃度計算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Apabetalone (RVX-208) is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. The IC50s are 87 μM and 0.51 μM for BD1 and BD2, respectively
  • 靶點: IC50: 510±41 nM (BD2), 87±10 μM (BD1);EpigeneticReaderDomain;HIVProtease
  • 體內(nèi)研究:
    In the atherosclerosis prophylactic treatment study design, mice are fed a Western diet concurrent with the treatment with 150 mg/kg/dose b.i.d. for 12 weeks. Mice are sacrificed at 12 weeks after treatment. There is a progressive increase in body weight in both the vehicle treated as well as the Apabetalone (RVX-208) treated groups. However, there is only an increase of 4 g (from 24 g to 28 g) body weight after 12 weeks on Western diet in the Apabetalone treated group whereas this increase is found to be 9 g (25 g-34 g) in the vehicle treated group. The significant decrease in body weight gain in Apabetalone treated mice is not due to decreased feed consumption, suggesting a positive attribute of the molecule. Plasma lipid measurements are done at 6 weeks and 12 weeks of treatment with either the vehicle or Apabetalone. Compared to the vehicle control animals, Apabetalone treated mice show significant increase (~200%) in the levels of HDL-C at 6 weeks of treatment, which is sustained until end of the study (12 weeks)
  • 參考文獻:
    1. Picaud S, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19754-9. 2. McLure KG, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One. 2013 Dec 31;8(12):e83190. 3. Jahagirdar R, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014 Sep;236(1):91-100.
  • 溶解性: DMSO  :  ≥  33  mg/mL  (89.09  mM)
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.7 ml 13.499 ml 26.998 ml
    5 mM 0.54 ml 2.7 ml 5.4 ml
    10 mM 0.27 ml 1.35 ml 2.7 ml
    50 mM 0.054 ml 0.27 ml 0.54 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。